RU2005132389A - Гуманизированное анти-cd4 антитело с иммунодепрессивными свойствами - Google Patents
Гуманизированное анти-cd4 антитело с иммунодепрессивными свойствами Download PDFInfo
- Publication number
- RU2005132389A RU2005132389A RU2005132389/13A RU2005132389A RU2005132389A RU 2005132389 A RU2005132389 A RU 2005132389A RU 2005132389/13 A RU2005132389/13 A RU 2005132389/13A RU 2005132389 A RU2005132389 A RU 2005132389A RU 2005132389 A RU2005132389 A RU 2005132389A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- antibody
- polynucleotide
- humanized anti
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (7)
1. Гуманизированное антитело (hB-F5), полученное из моноклонального антитела B-F5 к CD4, содержащее вариабельные (V) домены, характеризующиеся следующими полипептидными последовательностями:
V домен тяжелой Н-цепи:
EEQLVESGGGLVKPGGSLRLSCAASGFSDCRMYWLRQAPGKGLEWIGVISVKSE NYGANYAESVRFTISRDDSKNTVYLQMNSLKTEDTAVYYCSASYYRYDVGAWFAYWGQGTLVTVSS (SEQ ID NO: 1);
V домен легкой L-цепи:
DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSYIYWYQQKPGQPPKLLIYLASILESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSRELPWTFGQGTKVEIK (SEQ ID NO: 2).
2. Фрагмент антитела hB-F5 по п.1, в котором вышеупомянутый фрагмент содержит вариабельные V домены SEQ ID NO: 1 и SEQ ID NO: 2.
3. Полинуклеотид, выбранный из группы, включающей полинуклеотид, включающий последовательность, кодирующую тяжелую цепь вариабельного домена SEQ ID NO: 1; полинуклеотид, включающий последовательность, кодирующую легкую цепь вариабельного домена SEQ ID NO: 2.
4. Полинуклеотид по п.3, выбранный из группы, включающей полинуклеотид, включающий последовательность SEQ ID NO: 3; полинуклеотид, включающий последовательность SEQ ID NO: 4.
5. Лекарственная композиция, в состав которой входит гуманизированное антитело по п.1 или фрагмент по п.2.
6. Применение гуманизированного антитела по п.1 или фрагмента по п.2 для приготовления иммунодепрессивной композиции.
7. Применение гуманизированного антитела по п.1 для активации регуляторных CD25+ CD4+ Т-клеток in vitro.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03290725 | 2003-03-21 | ||
| EP03290725.5 | 2003-03-21 | ||
| EP03290942.6 | 2003-04-16 | ||
| EP03290942A EP1460088A1 (en) | 2003-03-21 | 2003-04-16 | Humanized anti-CD4 antibody with immunosuppressive properties |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005132389A true RU2005132389A (ru) | 2006-06-27 |
| RU2375375C2 RU2375375C2 (ru) | 2009-12-10 |
Family
ID=32826809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005132389/13A RU2375375C2 (ru) | 2003-03-21 | 2004-03-19 | Гуманизированное анти-cd4 антитело с иммунодепрессивными свойствами |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US7452981B2 (ru) |
| EP (4) | EP1460088A1 (ru) |
| JP (1) | JP4491454B2 (ru) |
| KR (2) | KR101276596B1 (ru) |
| AT (2) | ATE520716T1 (ru) |
| AU (1) | AU2004222089B2 (ru) |
| CA (1) | CA2519620C (ru) |
| CY (2) | CY1109390T1 (ru) |
| DE (1) | DE602004021702D1 (ru) |
| DK (2) | DK2070948T3 (ru) |
| ES (1) | ES2327523T3 (ru) |
| IL (2) | IL169657A (ru) |
| MX (1) | MXPA05009953A (ru) |
| NZ (1) | NZ541523A (ru) |
| PL (2) | PL1654286T3 (ru) |
| PT (2) | PT2070948E (ru) |
| RU (1) | RU2375375C2 (ru) |
| SG (1) | SG159392A1 (ru) |
| SI (2) | SI2070948T1 (ru) |
| WO (1) | WO2004083247A1 (ru) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1460088A1 (en) * | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
| US7947464B2 (en) * | 2005-08-02 | 2011-05-24 | Centenary Institute Of Cancer Medicine And Cell Biology | Method for identifying regulatory T cells |
| TW200817438A (en) * | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
| ES2825718T3 (es) | 2007-02-01 | 2021-05-17 | Univ Der Johannes Gutenberg Univ Mainz | Activación específica de una célula T reguladora y su uso para el tratamiento del asma, enfermedades alérgicas, enfermedades autoinmunes, rechazo de injertos y para la inducción de tolerancia |
| CL2008000707A1 (es) * | 2007-03-13 | 2008-09-22 | Hoffmann La Roche | Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion. |
| US20090022720A1 (en) * | 2007-07-20 | 2009-01-22 | Stephan Fischer | Conjugate of an antibody against CD4 and antifusogenic peptides |
| EP2592147A1 (en) | 2007-10-12 | 2013-05-15 | F. Hoffmann-La Roche AG | Protein expression from multiple nucleic acids |
| CA2718191C (en) * | 2008-03-13 | 2018-05-15 | Biotest Ag | Agent for treating disease |
| KR20100135808A (ko) * | 2008-03-13 | 2010-12-27 | 바이오테스트 아게 | 질병 치료제 |
| CN102027017A (zh) * | 2008-03-13 | 2011-04-20 | 生物测试股份公司 | 一种治疗疾病的试剂 |
| CA2716919C (en) * | 2008-03-14 | 2015-01-20 | Biocon Limited | An anti-cd6 monoclonal antibody and use thereof |
| US8637466B2 (en) | 2008-08-11 | 2014-01-28 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
| DK2341937T3 (en) * | 2008-09-29 | 2015-02-09 | Biotest Ag | Composition for the treatment of a disease |
| GB0920944D0 (en) * | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
| US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| WO2012088422A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| WO2012166555A1 (en) | 2011-05-27 | 2012-12-06 | Nektar Therapeutics | Water - soluble polymer - linked binding moiety and drug compounds |
| JP2016539927A (ja) | 2013-10-24 | 2016-12-22 | アッヴィ・インコーポレイテッド | Ｊａｋ１選択的阻害剤とその使用 |
| WO2015125652A1 (ja) * | 2014-02-21 | 2015-08-27 | Ｉｄａｃセラノスティクス株式会社 | 固形がんの治療剤 |
| JP6830437B2 (ja) | 2014-12-10 | 2021-02-17 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 疾患を処置するための遺伝子改変された細胞、組織および臓器 |
| SG11201802990RA (en) | 2015-10-16 | 2018-05-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| MY201573A (en) | 2017-05-12 | 2024-03-02 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| CN112105420A (zh) | 2018-05-11 | 2020-12-18 | 克里斯珀医疗股份公司 | 用于治疗癌症的方法和组合物 |
| EP3820888A4 (en) | 2018-07-13 | 2022-04-27 | Nanjing Legend Biotech Co., Ltd. | CO-RECEPTOR SYSTEMS FOR THE TREATMENT OF INFECTIOUS DISEASES |
| EP3962535A1 (en) | 2019-04-30 | 2022-03-09 | CRISPR Therapeutics AG | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| TW202321457A (zh) | 2021-08-04 | 2023-06-01 | 美商薩那生物科技公司 | 靶向ｃｄ４之病毒載體之用途 |
| WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| US20250082777A1 (en) | 2022-01-10 | 2025-03-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250144235A1 (en) | 2022-02-02 | 2025-05-08 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| US20260027145A1 (en) | 2022-07-27 | 2026-01-29 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| CN120569191A (zh) | 2022-11-23 | 2025-08-29 | 乔治亚大学研究基金公司 | 用于增加免疫应答的组合物及其使用方法 |
| EP4627096A1 (en) | 2022-12-02 | 2025-10-08 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| CN121443743A (zh) | 2023-05-23 | 2026-01-30 | 赛纳生物技术公司 | 串联融合剂和相关脂质颗粒 |
| GB202401501D0 (en) * | 2024-02-05 | 2024-03-20 | T Balance Therapeutics Gmbh | Medical use of regulatory t cell activator |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| CN118978596B (zh) * | 2024-09-24 | 2025-01-28 | 北京同立海源生物科技有限公司 | 针对cd4蛋白的单克隆抗体及其用途 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT90657B (pt) | 1988-05-27 | 1995-03-01 | Ortho Pharma Corp | Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora |
| JPH0768273B2 (ja) | 1988-12-02 | 1995-07-26 | カルピス食品工業株式会社 | 抗ｈｉｖペプチド |
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1990013562A1 (en) | 1989-05-02 | 1990-11-15 | Genelabs Incorporated | Chemically modified cd4 peptide fragments having anti-retroviral properties |
| GB8912497D0 (en) | 1989-05-31 | 1989-07-19 | Cobbold Stephen P | Monoclonal antibodies |
| US5690933A (en) | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US20020099179A1 (en) * | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| HUT60768A (en) | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
| US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
| WO1992009305A1 (en) * | 1990-11-27 | 1992-06-11 | Biogen, Inc. | Anti cd-4 antibodies blocking hiv-induced syncytia |
| US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5777085A (en) * | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| IL101769A (en) | 1992-05-03 | 2007-02-11 | Yeda Res & Dev | Modulation of TNF receptor action |
| US5741488A (en) | 1992-10-08 | 1998-04-21 | The Kennedy Institute For Rheumatology | Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies |
| US6270766B1 (en) | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
| ES2159529T5 (es) | 1993-03-05 | 2011-03-09 | Bayer Corporation | Anticuerpos monoclonales humanos anti-tnf alfa. |
| EP0631783A1 (en) | 1993-06-03 | 1995-01-04 | Mitsubishi Chemical Corporation | Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives |
| JPH09510952A (ja) | 1993-10-06 | 1997-11-04 | ザ ケネディー インスティチュート オブ リューマトロジー | 自己免疫疾患および炎症性疾患の治療 |
| US20020068057A1 (en) | 1994-03-10 | 2002-06-06 | Marc Feldmann | Treatment of autoimmune and inflammatory disorders |
| US5683693A (en) * | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
| EP0840618B1 (en) | 1995-05-18 | 2003-04-23 | Ortho-McNeil Pharmaceutical, Inc. | Induction of immunological tolerance by the use of non-depleting anti-cd4 antibodies |
| US6258562B1 (en) | 1996-02-09 | 2001-07-10 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US20010056066A1 (en) | 1996-07-26 | 2001-12-27 | Smithkline Beecham Corporation | Method of treating immune cell mediated systemic diseases |
| AU4563197A (en) | 1996-10-01 | 1998-04-24 | Celltech Therapeutics Limited | Pharmaceutical products containing protein-tyrosine kinase inhibitors and anti-cd4 antibodies |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| DE19722888A1 (de) | 1997-05-28 | 1998-12-03 | Thomas Prof Dr Huenig | Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten |
| AU3633000A (en) | 1999-03-26 | 2000-10-16 | Human Genome Sciences, Inc. | Neutrokine-alpha binding proteins and methods based thereon |
| JP4286483B2 (ja) | 1999-06-09 | 2009-07-01 | イムノメディクス， インコーポレイテッド | Ｂ細胞をターゲットとする抗体を使用する自己免疫疾患に対する免疫療法 |
| AU6941000A (en) | 1999-08-27 | 2001-03-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Polypeptides that bind hiv gp120 and related nucleic acids, antibodies, compositions, and methods of use |
| US7304127B2 (en) | 1999-08-27 | 2007-12-04 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use |
| AU2001275186A1 (en) | 2000-06-02 | 2001-12-17 | Nicole Kirchhof | Immunotherapeutic method to prevent islet cell rejection |
| MXPA03002262A (es) | 2000-09-18 | 2003-10-15 | Idec Pharma Corp | Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b. |
| DE10050935A1 (de) | 2000-10-11 | 2002-05-02 | Tegenero Gmbh | Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen |
| US6726923B2 (en) | 2001-01-16 | 2004-04-27 | Vascular Therapies, Llc | Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts |
| IL157794A0 (en) | 2001-03-07 | 2004-03-28 | Childrens Medical Center | Method to screen peptide display libraries using minicell display |
| EP1241249A1 (en) * | 2001-03-12 | 2002-09-18 | Gerold Schuler | CD4+CD25+regulatory T cells from human blood |
| CA2444821C (en) | 2001-04-24 | 2012-07-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Combination therapy using anti-angiogenic agents and tnfa |
| WO2002102853A2 (en) | 2001-06-14 | 2002-12-27 | Isis Innovation Limited | Cd4-specific antibody trx1 and uses therefor |
| US7541443B2 (en) | 2001-06-14 | 2009-06-02 | Tolerrx, Inc. | Anti-CD4 antibodies |
| GB2376466A (en) | 2001-06-14 | 2002-12-18 | Mark Frewin | TRX1 antibody |
| EP1451224B1 (de) | 2001-12-04 | 2012-08-15 | TheraMAB LLC | Peptid oder protein enthaltend ein c'-d loop der cd28 rezeptorfamilie |
| DE10212108A1 (de) | 2002-03-13 | 2003-10-02 | Tegenero Ag | Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung |
| DE10230223A1 (de) | 2002-07-04 | 2004-01-22 | Tegenero Ag | Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern |
| AU2003291625B2 (en) | 2002-09-16 | 2009-10-08 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| US7501494B2 (en) | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
| EP1460088A1 (en) | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
| RU2358762C9 (ru) | 2003-04-09 | 2016-10-10 | Джинентех, Инк. | Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа |
| GB0314461D0 (en) | 2003-06-20 | 2003-07-23 | Isis Innovation | Suppression of transplant rejection |
| EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
| EP1600164A3 (de) | 2003-09-22 | 2006-05-17 | TeGenero AG | Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung |
| DE10352900A1 (de) | 2003-11-11 | 2005-06-16 | Tegenero Ag | Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL |
| SG177944A1 (en) | 2005-07-11 | 2012-02-28 | Macrogenics Inc | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| KR20100135808A (ko) | 2008-03-13 | 2010-12-27 | 바이오테스트 아게 | 질병 치료제 |
| CN102027017A (zh) * | 2008-03-13 | 2011-04-20 | 生物测试股份公司 | 一种治疗疾病的试剂 |
| CA2718191C (en) | 2008-03-13 | 2018-05-15 | Biotest Ag | Agent for treating disease |
| DK2341937T3 (en) | 2008-09-29 | 2015-02-09 | Biotest Ag | Composition for the treatment of a disease |
| GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
-
2003
- 2003-04-16 EP EP03290942A patent/EP1460088A1/en not_active Withdrawn
-
2004
- 2004-03-19 PL PL04721843T patent/PL1654286T3/pl unknown
- 2004-03-19 PT PT09153544T patent/PT2070948E/pt unknown
- 2004-03-19 EP EP09153544A patent/EP2070948B1/en not_active Expired - Lifetime
- 2004-03-19 SI SI200431769T patent/SI2070948T1/sl unknown
- 2004-03-19 DK DK09153544.3T patent/DK2070948T3/da active
- 2004-03-19 SI SI200431225T patent/SI1654286T1/sl unknown
- 2004-03-19 PL PL09153544T patent/PL2070948T3/pl unknown
- 2004-03-19 AT AT09153544T patent/ATE520716T1/de active
- 2004-03-19 AT AT04721843T patent/ATE434626T1/de active
- 2004-03-19 CA CA2519620A patent/CA2519620C/en not_active Expired - Lifetime
- 2004-03-19 EP EP04721843A patent/EP1654286B1/en not_active Expired - Lifetime
- 2004-03-19 KR KR1020057016180A patent/KR101276596B1/ko not_active Expired - Fee Related
- 2004-03-19 MX MXPA05009953A patent/MXPA05009953A/es active IP Right Grant
- 2004-03-19 NZ NZ541523A patent/NZ541523A/en not_active IP Right Cessation
- 2004-03-19 JP JP2006504748A patent/JP4491454B2/ja not_active Expired - Lifetime
- 2004-03-19 DK DK04721843T patent/DK1654286T3/da active
- 2004-03-19 PT PT04721843T patent/PT1654286E/pt unknown
- 2004-03-19 AU AU2004222089A patent/AU2004222089B2/en not_active Ceased
- 2004-03-19 WO PCT/EP2004/002888 patent/WO2004083247A1/en not_active Ceased
- 2004-03-19 ES ES04721843T patent/ES2327523T3/es not_active Expired - Lifetime
- 2004-03-19 DE DE602004021702T patent/DE602004021702D1/de not_active Expired - Lifetime
- 2004-03-19 EP EP10179921.1A patent/EP2332991B1/en not_active Expired - Lifetime
- 2004-03-19 KR KR1020137007946A patent/KR20130042654A/ko not_active Ceased
- 2004-03-19 SG SG200708377-7A patent/SG159392A1/en unknown
- 2004-03-19 RU RU2005132389/13A patent/RU2375375C2/ru not_active IP Right Cessation
-
2005
- 2005-07-13 IL IL169657A patent/IL169657A/en not_active IP Right Cessation
- 2005-09-02 US US11/217,402 patent/US7452981B2/en not_active Expired - Lifetime
-
2008
- 2008-10-07 US US12/246,660 patent/US8586715B2/en not_active Expired - Fee Related
-
2009
- 2009-02-25 US US12/392,493 patent/US8440806B2/en not_active Expired - Fee Related
- 2009-02-25 US US12/392,556 patent/US8685651B2/en not_active Expired - Fee Related
- 2009-02-25 US US12/392,521 patent/US8673304B2/en not_active Expired - Lifetime
- 2009-09-21 CY CY20091100972T patent/CY1109390T1/el unknown
-
2011
- 2011-05-17 IL IL212949A patent/IL212949A/en not_active IP Right Cessation
- 2011-11-16 CY CY20111101102T patent/CY1112044T1/el unknown
-
2014
- 2014-02-10 US US14/176,485 patent/US9758581B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005132389A (ru) | Гуманизированное анти-cd4 антитело с иммунодепрессивными свойствами | |
| CY1118709T1 (el) | Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf | |
| RU2011115845A (ru) | Антитело против глипикана 3 | |
| RU2020124623A (ru) | Антитела, специфичные к гетеродимеру cd3-дельта/эпсилон | |
| RU2011140509A (ru) | Гетеродимерные полипептиды il-17a/f и возможности их лечебного применения | |
| PE20070183A1 (es) | Anticuerpos monoclonales anti-trkb | |
| NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| FI3558369T3 (fi) | Spesifisesti ihmisen il-15:een sitoutuvia vasta-aineita ja niiden käyttötapoja | |
| NZ584838A (en) | Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof | |
| NZ587198A (en) | Monoclonal antibodies against the rgm a protein and uses thereof | |
| RU2014114172A (ru) | Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом | |
| RU2531523C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| RU2009111884A (ru) | Последовательности вариабельных областей моноклональных антител против il-31 и способы использования | |
| RU2008111882A (ru) | Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38 | |
| HRP20150641T1 (hr) | Anti -cd38 humana antitijela i njihove uporabe | |
| DE19975033I2 (de) | CD25-bindende Molek}le | |
| SG151284A1 (en) | Antibodies against ccr5 and uses thereof | |
| NZ585622A (en) | Hepatitis c virus antibodies | |
| SI2481753T1 (en) | Anti-IL-17 antibodies | |
| AR125212A1 (es) | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas | |
| RU2011151287A (ru) | АНТИ Notch-1 АНТИТЕЛА | |
| RU2012137380A (ru) | Моноклональные антитела к cd44, предназначенные для применения при лечении плоскоклеточной карциномы головы и шеи | |
| RU2012105045A (ru) | Моноклональное антитело человека против альфа-токсина из s. aureus и его применение в лечении или предотвращении образования абсцесса | |
| RU2014127287A (ru) | Антитела, используемые для пассивной вакцинации против гриппа | |
| RU2014106933A (ru) | Способы и композиции для лечения аутоиммунных и воспалительных заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20200320 |